Three-year adjuvant treatment with osimertinib improves disease-free survival (DFS) and overall survival (OS) and reduces central nervous system (CNS) recurrence in patients with EGFR-mutated non-small cell lung cancer resection at stage IB–IIIA. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.